Table 3.

Pharmaceutical formulations with proteins and genes targeting neurodegenerative disorders using other nanosystems.

Active Molecule	Formulation	Targeting Disease	Method	Ref.
NGF	Porous silicon nanostructures	Neuroprotection	In vivo	[136]
Plasmid containing α-synuclein RNAi	Oleic acid-coated iron oxide nanoparticles	PD	In vivo male C57BL/6 mice	[137]
pDNA	Gold nanoparticles	PD	In vivo male C57BL/6 mice	[138]
THRPPMWSPVWP peptide sequence	Gold nanoparticles	AD	In vivo Male Sprague rats	[139]
TPM (tetrapeptide from maize)	Gold nanoparticles	AD	In vivo female KM mice	[140]
Plasmid DNA	Gold nanoparticles	PD	In vivo C57bl/6 mice	[141]
D1 and Ang2 peptides	Gold nanorods	AD	In vivo Caenorhabditis elegans AD model	[142]
NGF	Poly(N-isopropylacrylamide), poly(L-lactic acid), and poly(L-lysine) dendrons	AD	In vitro	[143]
siRNA	RGV-Cyclodextrin nanoparticles	HD	In vitro	[144]